Paratek Patent-Cliff Exposure & CMS Drug Spending Portfolio

Paratek (US): 2 reconciled FDA prescription therapies (80.5% 2025 to 2030 cliff risk), $156.8M 2024 CMS Part D & Medicaid spend, and 9 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies2
2025 to 2030 Patent-Cliff Revenue Exposure80.5%
Primary Portfolio LOE Date2036-01-01
2024 CMS Total Public Spend$156.8M
2024 Medicare Part D Spend$126.6M
2024 Medicaid Spend$30.2M
California HCAI SB 17 Filings9 WAC filings (max 23.5% 2-yr change)